SCHEMBL17799731

SCHEMBL17799731

O=C(N[C@H]1CC[C@H]1c1ccc(Cl)cc1Cl)c1cccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ RAB9A P51151 5/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ MEN1 O00255 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ APOBEC3A P31941 1/20 0.49
▸ APOBEC3G Q9HC16 1/20 0.49
▸ ALDH1A1 P00352 5/20 0.48
▸ GAA P10253 4/20 0.48
▸ ATM Q13315 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ HPGD P15428 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ KCNMA1 Q12791 1/20 0.46
▸ LMNA P02545 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17799764 0.84 TAS1R3 (0.52) RAB9ANPC1MEN1KMT2AGAA
SCHEMBL17799645 0.82 GAA (0.44) TSHRRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL17799654 0.82 F10 (0.43) RAB9ASMN1; SMN2MEN1KMT2AGAA
SCHEMBL17799737 0.81 RAB9A (0.46) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL16220951 0.80 L3MBTL1 (0.57) RAB9ANPC1MEN1KMT2AL3MBTL1
SCHEMBL17799697 0.80 NPC1 (0.40) TSHRRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL17799691 0.80 TSHR (0.56) TSHRHSD17B10RAB9ANPC1SMN1; SMN2
SCHEMBL17799675 0.79 RAB9A (0.44) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL17799763 0.79 RAB9A (0.44) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL17799743 0.79 SLC6A12 (0.47) RAB9ANPC1ALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS TSHR 3672/4885HSD17B10 2938/4885RAB9A 1776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback